期刊文献+

循环应用低剂量环磷酰胺对黑色素瘤荷瘤小鼠调节性T细胞的影响及抗瘤作用 被引量:4

Influence of Cyclical Administration with Low-dose Cyclophosphamide on Regulatory T Cells of Melanoma-bearing Mice and Its Antitumor Effect
原文传递
导出
摘要 目的观察循环应用低剂量环磷酰胺(CTX)对黑色素瘤荷瘤小鼠调节性T细胞(Treg)的影响及抗瘤作用。方法通过皮下接种黑色素瘤细胞B16制备黑色素瘤荷瘤小鼠模型;对荷瘤小鼠分别经腹腔单次或循环注射CTX,每隔7d给药1次,共3次,应用流式细胞术检测小鼠脾脏中CD4+CD25+Foxp3+Treg的含量;培养小鼠骨髓来源的树突状细胞(DC),将DC与脾T淋巴细胞混合培养,应用ELISA法检测脾T淋巴细胞干扰素γ(IFNγ)的分泌量;同时测量肿瘤的大小,绘制肿瘤生长曲线,并观察各组荷瘤小鼠自身免疫病的发生情况。结果CTX的最佳应用剂量为100mg/kg。随着荷瘤时间的延长,荷瘤小鼠脾脏CD4+CD25+Foxp3+/CD4+的比值呈逐渐升高趋势。单次应用CTX抑制Treg的时间较短,而循环应用CTX能够延长对Treg的抑制,使其维持在相对较低的水平;循环应用CTX显著提高了荷瘤小鼠脾T淋巴细胞IFNγ的分泌水平。单次和循环应用CTX均未能延缓肿瘤的生长,两组小鼠均未见免疫性白斑及明显的化疗毒副反应。结论循环应用CTX能更加有效地调控Treg,从而促进DC对T淋巴细胞的抗原特异性激活,这将会提高DC疫苗的抗瘤效果。 Objective To observe the influence of cyclical administration with low-dose cyclophosphamide(CTX)on regulatory T cells(Treg)of melanoma-bearing mice and its antitumor effect. Methods Melanoma-bearing mouse model was established by inoculating s.c. mice with melanoma B16 cells. The model mice were injected i.p. with CTX once or every 7 d for 3 times, and determined for CD4+CD25+Foxp3+ Treg content in spleens by flow cytometry. The onsets of autoimmune diseases of model mice in various groups were observed. Mouse bone marrow-derived dendritic cells (DCs)were cultured, then co-cultured with the splenic T lymphocytes of model mice and determined for the secretion level of IFNγ by ELISA. The size of tumor was measured, based on which a tumor growth curve was plotted. Results The optimal dosage of CTX was 100 mg / kg. The CD4+CD25+Foxp3+ / CD4+ ratio in spleens of model mice showed an increasing tendency with the increasing time for melanoma-bearing. The inhibitory effect of a single administration with CTX on Treg lasted for a short time. However, the cyclical administration with CTX prolonged the inhibitory effect, maintaining Treg at a relatively low level. Meanwhile, the cyclical administration with CTX increased the secretion level of IFNγ in splenic T lymphocytes of melanoma-bearing mice. Neither a single administration nor cyclical administration with CTX delayed the growth of tumor. No immune white spots or obvious chemotherapy-associated adverse effects were observed in mice treated with CTX by a single administration and cyclical administration. Conclusion The cyclical administration with CTX was more effective for regulating Treg, thus promoted the antigen specific activation of T lymphocytes by DCs and enhanced the anti-tumor effect of DC vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第4期403-407,共5页 Chinese Journal of Biologicals
基金 河北省科技厅博士基金资助项目(04547002D29) 河北省医学适用技术跟踪项目(GL200938)
关键词 环磷酰胺 黑色素瘤 调节性T细胞 树突状细胞 Cyclophosphamide(CTX) Melanoma Regulatory T cells(Treg) Dendritic cells(DCs)
  • 相关文献

参考文献11

  • 1Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest, 2007, 117 (5): 1167-1174.
  • 2Ghiringheli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T ceils suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004, 34 (2): 336-344.
  • 3Schabowsky RH, Madireddi S, Sharma R, et al. Targeting CD4+ CD25 +FoxP3 + regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs, 2007, 8 (12): 1002- 1008.
  • 4Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007, 178(5): 2883-2892.
  • 5Jordan JT, Sun W, Hussain SF, et al. Preferential migration of regulatory T cells mediated by glioma-seereted chemokines can be blocked with chemotherapy. Cancer lmmunol Immunother, 2008, 57 (1): 123-131.
  • 6Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol, 2005, 6 (4): 338-344.
  • 7Smyth MJ, Teng MW, Swann J, et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol, 2006, 176 (3): 1582-1587.
  • 8Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4 (+) CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother, 2007, 56 (1): 48-59.
  • 9Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep, 2006, 16 (1): 141-146.
  • 10Matsushita N, Pilon-Thomas SA, Martin LM, et al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods, 2008, 333 (1-2): 167-179.

同被引文献43

  • 1Klebanoff CA, Acquavella N, Yu Z, et ol. Therapeutic cancer vaccines: are we there yet [J]. Immunol Rev, 2011, 239 (1): 27- 44.
  • 2Draube A, Klein-Gonza1ez N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a sys- tematic review and meta-analysis [J]. PLoS One, 2011, 6 (4): e18801.
  • 3Palucka K, Ueno H, Fay J, et al. Dendritic cells and immunity a- gainst cancer [J]. J Intern Med, 2011, 269 (1): 64-73.
  • 4Brode S, Cooke A. Immune-potentiating effects of the chemothera- peutic drug cyclophosphamide [J]. Crit Rev Immunol, 2008, 28 (2): 109-126.
  • 5Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ reg- ulatory T cells in immunological tolerance to serf and non-self [J]. Nat Immunol, 2005, 6 (4): 345-352.
  • 6Cao X. Regulatory T ceils and immune tolerance to tumors [J]. Immunol Res, 2010, 46 (1-3): 79-93.
  • 7Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4+ CD25+ regulatory T cell suppression of dendritic cell function in- volves TGF-beta and IL-10 [J]. Cancer Immunol Immunother, 2007, 56 (1) : 48-59.
  • 8Chakraborty NG, Chattopadhyay S, Mehrotra S, et al. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma [J]. Hum Irrmmnol, 2004, 65 (8): 794-802.
  • 9Kudo-Saito C, Schlom J, Camphausen K, et ol. The requirement of multimodal therapy (vaccine, local tumor radiation, and re- duction of suppressor cells) to eliminate established tumors [J]. Clin Cancer Res, 2005, 11 (12): 4533-4544.
  • 10Matsushita N, Pilon-Thomas SA, Martin LM, et ol. Comparative methodologies of regulatory T cell depletion in a murine melanoma model [J]. J Immunol Methods, 2008, 333 (1-2): 167-179.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部